

## Otonomy Inc

### CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 06-Jun-2015

#### THOMSON REUTERS

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



## ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

### DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drug Pipeline Detail..... 9

    Pre-registration..... 10

    Phase 2 Clinical..... 13

    Discovery..... 18

[Return to Table of Contents](#)

## COMPANY OVERVIEW

<b>Company Name</b>	Otonomy Inc
<b>Parent Company Name</b>	Otonomy Inc
<b>Website</b>	http://www.otonomy.com/
<b>Country</b>	US
<b>Number of Drugs in Active Development</b>	3
<b>Number of Inactive Drugs</b>	0
<b>Number of Patents as Owner</b>	13
<b>Number of Patents as Third Party</b>	0
<b>Number of Deals</b>	2
<b>Key Indications</b>	Ear disease, Meniere disease, Tinnitus, Otitis media, Hearing disorder, Chronic sinusitis, Fungal infection, Hearing loss, Nasal polyps, Epistaxis, Nasopharyngeal carcinoma, Nose disease, Otitis externa, Sensorineural hearing loss, Vertigo
<b>Key Target-based Actions</b>	Glucocorticoid agonist, DNA gyrase inhibitor, Topoisomerase IV inhibitor, NMDA receptor antagonist
<b>Key Technologies</b>	Otic gel formulation, Small molecule therapeutic, Sustained release formulation, Otic formulation, Injectable controlled release formulation, Steroid, Antibiotic, Parenteral formulation unspecified, Liquid-based formulation technology, Microparticle formulation

## COMPANY PROFILE

### SUMMARY

Otonomy, founded in 2008, is a spin-off from the UC San Diego. It is an emerging biopharmaceutical company dedicated to developing and marketing therapeutics designed specifically for the middle and inner ear.

### COMPANY LOCATION

In May 2015, the company entered into a lease agreement with ARE-SD Region No. 34, LLC for the lease of an approximately 61,755 square foot building to be constructed at 4796 Executive Drive, San Diego, California. The new building would accommodate growth of the Otonomy team to support commercialization efforts and development of an expanding product pipeline. The construction of the building was expected to complete in October 2016.

### FINANCIAL

In January 2015, the company priced its follow-on public offering of 2,550,000 shares of its common stock at \$29.25 each, for total gross proceeds of approximately \$75 million. The offering was expected to close on January 28, 2015. The underwriters were granted a 30-day option to purchase up to an additional 382,500 shares of common stock. A registration statement relating to securities had been filed with the SEC and became effective on January 22, 2015; Later that month, the offering was closed, with total gross proceeds of approximately \$86 million and net proceeds of approximately \$80 million.

In January 2015, the company filed a registration statement on Form S-1 for the proposed follow-on public offering of \$75 million of its common stock. At that time, the company planned to grant the underwriters a 30-day option to purchase up to an additional \$11.25 million of its common stock. Later that month, the follow-on public offering was launched.

In October 2014, Otonomy was added to the Russell 2000 Index.

In July 2014, the company filed a registration statement on Form S-1 for the proposed initial public offering. In August 2014, the company priced its initial public offering of 6,250,000 shares of common stock, at \$16 each. The underwriters were granted a 30-day option to purchase up to an additional 937,500 shares of common stock. At that time, the shares began trading on NASDAQ global select market under the symbol "OTIC". In September 2014, the underwriters purchased the additional 937,500 shares at \$16 each. The company raised \$104 million through the offering.

[Return to Table of Contents](#)



In April 2014, the company raised \$49 million from an oversubscribed series D financing round.

In September 2013, Otonomy raised \$45.9 million in a series C financing round.

In August 2010, the company raised \$38.5 million from a series B financing round.


In June 2010, the company raised \$10 million from a series A financing round.

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Otorhinolaryngological disease	3	0	3

[Return to Table of Contents](#)

## Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Pre-registration	1
Phase 2 Clinical	1
Discovery	1

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Asset Divestment	0	0	1	0	1
Drug - Early Research/Development	0	0	1	0	1

## CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Otorhinolaryngological disease	2	8

[Return to Table of Contents](#)



## Trials by Phase

Phase	Ongoing	All
Phase 3	0	3
Phase 2	2	3
Phase 1	0	2

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	1	0	1
Immune disorder	1	0	1
Neoplasm	1	0	1
Mouth disease	1	0	1
Neurological disease	4	0	4
Respiratory disease	1	0	1
Infectious disease	1	0	1
Injury	1	0	1
Inflammatory disease	1	0	1
Otorhinolaryngological disease	9	0	9

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)





## PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### ciprofloxacin (intratympanic sustained release gel, otitis media), Otonomy

#### ciprofloxacin (intratympanic sustained release gel, otitis media), Otonomy SNAPSHOT

<b>Drug Name</b>	ciprofloxacin (intratympanic sustained release gel, otitis media), Otonomy
<b>Key Synonyms</b>	ciprofloxacin;AuriPro
<b>Originator Company</b>	Otonomy Inc
<b>Active Companies</b>	Otonomy Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Pre-registration
<b>Active Indications</b>	Otitis media
<b>Target-based Actions</b>	DNA gyrase inhibitor;Topoisomerase IV inhibitor
<b>Other Actions</b>	Bacterial nucleic acid synthesis inhibitor;Antibacterial
<b>Technologies</b>	Small molecule therapeutic;Parenteral formulation unspecified;Otic gel formulation;Antibiotic;Sustained release formulation
<b>Last Change Date</b>	13-May-2015

#### ciprofloxacin (intratympanic sustained release gel, otitis media), Otonomy DEVELOPMENT PROFILE

##### SUMMARY

Otonomy is developing AuriPro (previously OTO-201; OTO-203), a sustained release gel formulation of ciprofloxacin, delivered using intratympanic injection, for the potential treatment of otitis media,. In February 2015, an NDA was submitted to the US FDA ; in April 2015, the NDA was accepted for review by the FDA. In March 2015, the company planned to launch the drug in the first quarter of 2016. In November 2013, the company was seeking to outlicense the drug.

#### ciprofloxacin (intratympanic sustained release gel, otitis media), Otonomy DEVELOPMENT STATUS


##### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Otonomy Inc	Otitis media	US	Pre-registration	25-Feb-2015
Otonomy Inc	Otitis media	Canada	Phase 3 Clinical	11-Dec-2013

#### ciprofloxacin (intratympanic sustained release gel, otitis media), Otonomy CHEMICAL STRUCTURES

[Return to Table of Contents](#)



CAS Registry Number:	Confidence Level:
85721-33-1	1
	
Name	Type
ciprofloxacin	BANN; INN; USAN
Pulmaquin	Trade Name
OTO-201	Research Code
OBM-A-03	Research Code
Cipro NDS	

#### ciprofloxacin (intratympanic sustained release gel, otitis media), Otonomy DRUG NAMES

Names	Type
AuriPro	Trade Name
OTO-201	Research Code
OTO-203	Research Code
ciprofloxacin (intratympanic sustained release gel, otitis media), Otonomy	
ciprofloxacin	BANN, INN, USAN

#### ciprofloxacin (intratympanic sustained release gel, otitis media), Otonomy CLINICAL TRIALS

##### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Otitis media											
0	0	0	3	1	1	0	1	0	0	1	5

[Return to Table of Contents](#)

## Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	3	1	1	0	1	0	0	1	5

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical


Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## ciprofloxacin (intratympanic sustained release gel, otitis media), Otonomy DEALS AND PATENTS

### PATENTS

#### Patents by Parent Company Chart

Chart displayed by Owner/Third Party




#### Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Otonomy Inc	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Product	1
Formulation	1

[Return to Table of Contents](#)

## dexamethasone (sustained release/intratympanic injection, ear disorders), Otonomy

### dexamethasone (sustained release/intratympanic injection, ear disorders), Otonomy SNAPSHOT

<b>Drug Name</b>	dexamethasone (sustained release/intratympanic injection, ear disorders), Otonomy
<b>Key Synonyms</b>	dexamethasone
<b>Originator Company</b>	Otonomy Inc
<b>Active Companies</b>	Otonomy Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Meniere disease;Ear disease
<b>Target-based Actions</b>	Glucocorticoid agonist
<b>Other Actions</b>	Steroidal anti-inflammatory
<b>Technologies</b>	Otic formulation;Injectable controlled release formulation;Small molecule therapeutic;Otic gel formulation;Steroid
<b>Last Change Date</b>	22-May-2015

### dexamethasone (sustained release/intratympanic injection, ear disorders), Otonomy DEVELOPMENT PROFILE

#### SUMMARY

Otonomy is developing OTO-104, a local-acting, sustained-release thermosensitive gel formulation of dexamethasone, delivered via intratympanic injection, for the potential injectable treatment of ear diseases, including Meniere disease. In November 2013, a phase II/III trial for Meniere disease was ongoing. In February 2011, the company planned to initiate clinical trials for noise- and chemotherapy-induced hearing loss. In August 2013, the company was advancing the formulation into late-stage clinical trials. In May 2015, positive data from the phase IIb trial were reported. In October 2014, a multiple dose safety, phase II trial of was initiated in UK and at that time, the company planned to start clinical development activities outside of North America. In April 2015, enrollment was completed into the multidose trial in the UK and at that time the trial was expected to be completed in March 2016. In September 2009, the company was seeking to outlicense the drug outside the US ; in November 2013, this was still the case.


### dexamethasone (sustained release/intratympanic injection, ear disorders), Otonomy DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Otonomy Inc	Meniere disease	Canada	Phase 2 Clinical	11-Dec-2013
Otonomy Inc	Meniere disease	UK	Phase 2 Clinical	20-Apr-2015
Otonomy Inc	Meniere disease	US	Phase 2 Clinical	11-Sep-2011
Otonomy Inc	Ear disease	US	Discovery	21-Sep-2009

[Return to Table of Contents](#)

## dexamethasone (sustained release/intratympanic injection, ear disorders), Otonomy CHEMICAL STRUCTURES

CAS Registry Number:	Confidence Level:
50-02-2	1
	
Name	Type
dexamethasone	BANN; INN
Dextenza	Trade Name
Ozurdex	Trade Name
Surodex	Trade Name
CD-102	Research Code
EGP-437	Research Code
OTO-104	Research Code
IBI-10090	Research Code
OTX-DP	Research Code
ISV-305	Research Code
TLC-x99	Research Code
Oncocort	

## dexamethasone (sustained release/intratympanic injection, ear disorders), Otonomy DRUG NAMES

Names	Type
dexamethasone (sustained release/intratympanic injection, ear disorders), Otonomy	
OTO-104	Research Code
dexamethasone	BANN, INN

[Return to Table of Contents](#)

## dexamethasone (sustained release/intratympanic injection, ear disorders), Otonomy CLINICAL TRIALS

### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Meniere disease											
0	0	0	0	1	2	0	1	0	0	1	3

### Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	1	2	0	1	0	0	1	3

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical


Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

dexamethasone (sustained release/intratympanic injection, ear disorders), Otonomy DEALS AND PATENTS

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Otonomy Inc	2	0	2
Individual	1	0	1
University of California	1	0	1

[Return to Table of Contents](#)



Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Formulation	1
Product	1
New use	1

## OTO-311

### OTO-311 SNAPSHOT

Drug Name	OTO-311
Key Synonyms	gacyclidine
Originator Company	DURECT Corp
Active Companies	Otonomy Inc
Inactive Companies	NeuroSystec Corp;DURECT Corp
Highest Status	Discovery
Active Indications	Tinnitus
Target-based Actions	NMDA receptor antagonist
Other Actions	Analgesic
Technologies	Nanoparticle formulation injectable;Otic formulation;Injectable controlled release formulation;Small molecule therapeutic;Local formulation unspecified;Drug implant;Sustained release formulation
Last Change Date	09-Jan-2015

### OTO-311 DEVELOPMENT PROFILE

#### SUMMARY

Otonomy under license from NeuroSystec, (under exclusive license from DURECT), is developing OTO-311 (NST-001), a squalene-based nanoparticle formulation of gacyclidine, an NMDA receptor antagonist delivered directly into the cochlear using Otonomy's proprietary drug delivery technology (previously delivered using Neuroject implantable continuous delivery system), for the potential injectable treatment of tinnitus,. In November 2014, Otonomy was planning clinical trials for the following year. In January 2015, the company planned to file an IND and initiate a phase I trial in 2015. In November 2013, the drug was listed as being in preclinical development and at that time, the company was seeking to outlicense the drug.

#### OTO-311 DEVELOPMENT STATUS


##### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Otonomy Inc	Tinnitus	US	Discovery	06-Nov-2013
DURECT Corp	Tinnitus	France	Discontinued	21-Jun-2004
NeuroSystec Corp	Tinnitus	France	Discontinued	31-Oct-2013

#### OTO-311 CHEMICAL STRUCTURES

[Return to Table of Contents](#)



CAS Registry Number:	Confidence Level:
68134-81-6	1
	
Name	Type
gacyclidine	INN
NST-001	Research Code
GK-11	Research Code

## OTO-311 DRUG NAMES

Names	Type
OTO-311	Research Code
gacyclidine	INN
NMDA receptor antagonist (nanoparticle implant, tinnitus), Otonomy	
NMDA antagonist (nanoparticle implant, tinnitus), NeuroSystec Corp	
NST-001	Research Code
gacyclidine (nanoparticle implant, tinnitus), NeuroSystec Corp	
NMDA receptor antagonist (nanoparticle implant, tinnitus), NeuroSystec Corp	

## OTO-311 CLINICAL TRIALS

### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Tinnitus											
0	0	0	0	0	0	0	1	0	0	0	1

[Return to Table of Contents](#)

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	0	1	0	0	0	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

OTO-311 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




[Return to Table of Contents](#)

## Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Otonomy Inc	0	0	2	0	2
NeuroSystem Corp	1	0	1	0	2
Ipsen	1	0	0	0	1
DURECT Corp	1	0	0	0	1

## Deals by Type Chart




## Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Early Research/Development	1	0	1
Drug - Asset Divestment	1	0	1
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Otonomy Inc	1	0	1
NeuroSystemec Corp	0	1	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Formulation	1

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

